FDMT (4D Molecular Therapeutics) Enterprise Value : $-267.65 Mil (As of Mar. 03, 2025)

4D Molecular Therapeutics Enterprise Value Chart

4D Molecular Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Enterprise Value	Get a 7-Day Free Trial															239.73	599.14	1,118.12	561.38	85.03

Competitive Comparison of 4D Molecular Therapeutics's Enterprise Value

For the Biotechnology subindustry, 4D Molecular Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4D Molecular Therapeutics's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where 4D Molecular Therapeutics's Enterprise Value falls into.

4D Molecular Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

4D Molecular Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

4D Molecular Therapeutics's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4D Molecular Therapeutics  (NAS:FDMT) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

4D Molecular Therapeutics's EV-to-EBIT for today is

4D Molecular Therapeutics's current Enterprise Value is $-267.65 Mil.
4D Molecular Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-168.38 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

4D Molecular Therapeutics's EV-to-EBITDA for today is:

4D Molecular Therapeutics's current Enterprise Value is $-267.65 Mil.
4D Molecular Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-161.94 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

4D Molecular Therapeutics's EV-to-Revenue for today is:

4D Molecular Therapeutics's current Enterprise Value is $-267.65 Mil.
4D Molecular Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

4D Molecular Therapeutics's EV-to-FCF for today is:

4D Molecular Therapeutics's current Enterprise Value is $-267.65 Mil.
4D Molecular Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-116.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4D Molecular Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of 4D Molecular Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

4D Molecular Therapeutics Business Description